Pacing Solutions for Immune Checkpoint Myocarditis and Associated Conduction Disorders
Myocarditis is a rare but serious immune-related adverse event associated with immune checkpoint inhibitors. Mortality from immune checkpoint inhibitor associated myocarditis (ICIMy) is high, and developing advanced atrioventricular block is associated with worse mortality. Among a single-center cohort of 103 patients diagnosed with ICIMy, we describe 9 patients who required cardiac pacing for complete heart block. We present our systematic approach to managing ICIMy with advanced atrioventricular block, emphasizing the use of an active fixation right ventricular lead and external pacemaker generator for temporary pacing. This allows for stable and prolonged temporary pacing over a period of 4 to 6 weeks before deciding on implantation of a permanent pacemaker. This strategy has the potential to minimize infection risk by avoiding the need for generator pocket formation while patients are undergoing immunosuppressive therapy for treatment of ICIMy and allows for patient mobility and participation in physical therapy.
Authors
- Nicholas King (ORCID: https://orcid.org/0000-0002-5322-1953)
- Jean‐Bernard Durand
- Anita Deswal (ORCID: https://orcid.org/0000-0002-6147-9591)
- Nicolas L. Palaskas (ORCID: https://orcid.org/0000-0001-7565-1797)
- Kaveh Karimzad (ORCID: https://orcid.org/0000-0001-5613-6335)
- Efstratios Koutroumpakis (ORCID: https://orcid.org/0000-0002-6757-6480)
- Andrea Ruiz-Jurado
- Keila C Ostos-Mendoza
- Cezar Iliescu
- Hyeon-Ju Ali
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- The University of Texas Health Science Center at Houston (US)
- Tecnológico de Monterrey (MX)
Publication Details
- Journal
- JACC Case Reports
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1016/j.jaccas.2024.103187
- Citations
- 3
- Primary Topic
- Viral Infections and Immunology Research
- Type
- article
- Field-Weighted Citation Impact
- 4.16
Funders
- Cancer Prevention and Research Institute of Texas
- Andrew Sabin Family Foundation
- Kiniksa Pharmaceuticals
- National Institutes of Health
- National Cancer Institute